See Credit Details Below
The U.S. capital markets remain an attractive source of capital for emerging companies in the life sciences sector. Life sciences continued to represent the most significant percentage by deal volume of IPO activity in 2019. Many of these IPOs were preceded by late stage (or mezzanine) private placements made principally to U.S. institutional investors.
During this One-Hour Briefing, Jennifer J. Carlson and Anna T. Pinedo of Mayer Brown LLP will discuss:
- Financing alternatives for pre-IPO companies;
- The late-stage (or “cross-over”) private placements market;
- Considering milestones when planning a financing strategy; and
- Post-IPO alternatives, including registered direct offerings, PIPE transactions, at the market offerings, and related financing considerations.
Program Level: Overview
Intended Audience: In-house counsel, outside attorneys, board members, corporate officers, compliance officers, accountants, finance and other allied professionals involved in the life sciences industry
Advanced Preparation: None